BEAM

Beam Therapeutics Inc

Oct 15 • 12:47PM ET

26.75

+1.33 5.23 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT ALNY SRPT SGMO BLUE CLLS VYGR ADVM

| Held by: ARKK IWM VTI ARKG XBI VB VBK IWO VXF IBB

Index	RUT	P/E	-	EPS (ttm)	-4.51	Insider Own	9.78%	Shs Outstand	100.76M	Perf Week	-0.93%
Market Cap	2.71B	Forward P/E	-	EPS next Y	-4.42	Insider Trans	-1.01%	Shs Float	91.27M	Perf Month	16.76%
Enterprise Value	1.71B	PEG	-	EPS next Q	-1.04	Inst Own	101.24%	Short Float	23.43%	Perf Quarter	30.81%
Income	-398.58M	P/S	44.90	EPS this Y	5.33%	Inst Trans	-8.05%	Short Ratio	8.27	Perf Half Y	54.80%
Sales	60.27M	P/B	2.57	EPS next Y	-2.00%	ROA	-30.05%	Short Interest	21.38M	Perf YTD	7.86%
Book/sh	10.39	P/C	2.35	EPS next 5Y	0.31%	ROE	-41.94%	52W High	35.25 -24.11%	Perf Year	8.21%
Cash/sh	11.37	P/FCF	-	EPS past 3/5Y	7.43% -20.88%	ROIC	-33.53%	52W Low	13.52 97.78%	Perf 3Y	-42.68%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.00% 412.30%	Gross Margin	63.53%	Volatility	9.23% 6.86%	Perf 5Y	-6.14%
Dividend TTM	-	EV/Sales	28.38	EPS Y/Y TTM	-155.64%	Oper. Margin	-739.94%	ATR (14)	1.66	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.75	Sales Y/Y TTM	-82.90%	Profit Margin	-661.31%	RSI (14)	63.03	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	6.75	EPS Q/Q	9.34%	SMA20	6.87%	Beta	2.39	Target Price	45.00
Payout	-	Debt/Eq	0.15	Sales Q/Q	-28.08%	SMA50	27.36%	Rel Volume	0.77	Prev Close	25.42
Employees	483	LT Debt/Eq	0.14	Earnings	Aug 05 BMO	SMA200	24.81%	Avg Volume	2.58M	Price	26.75
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.12% -33.69%	Trades		Volume	1,051,746	Change	5.23%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-25	Initiated	Jefferies	Buy	$41
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy	$42
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$40
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117

Show Previous Ratings

Oct-11-25 10:02AM	Jim Cramer on Beam Therapeutics: "That's the Speculative Bottom There" (Insider Monkey)
Oct-08-25 12:57AM	What Does Wall Street Think About Beam Therapeutics (BEAM)? (Insider Monkey) +7.44%
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV)
Sep-18-25 11:35AM	3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 (Zacks) +11.80%
Sep-17-25 02:18PM	H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum (Insider Monkey)
11:30AM	Loading…
Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-28-25 08:48AM	CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now? (Zacks)
Aug-25-25 07:00AM	Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences (GlobeNewswire)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
Aug-20-25 12:13AM	JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating (Insider Monkey)
Aug-14-25 07:00AM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-06-25 11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
Aug-05-25 08:15AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jul-30-25 10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-29-25 10:00AM	Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-16-25 09:38AM	Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company (Insider Monkey)
Jul-09-25 10:45AM	Innovation ETF (ARKK) Hits New 52-Week High (Zacks) +5.71%
Jul-06-25 04:15AM	H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT (Insider Monkey)
Jul-03-25 09:18AM	Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease Trial (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-19-25 07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
Jun-13-25 07:00AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
11:30AM	Loading…
Jun-05-25 11:30AM	Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
Jun-03-25 07:00AM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
May-29-25 11:54PM	FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)' AATD Gene Therapy (Insider Monkey)
04:01PM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-14-25 09:30AM	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
May-13-25 07:00AM	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-12-25 04:01PM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks) +6.32%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)
12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
10:58AM	Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:43AM	Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
May-07-25 08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
May-06-25 05:05PM	Why Beam Therapeutics Stock Tanked on Tuesday (Motley Fool) -19.32%
01:37PM	Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down (Zacks)
11:07AM	Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)
09:17AM	RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates (Zacks)
08:20AM	Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-05-25 04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-02-25 01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
12:21PM	Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings (Zacks)
11:10AM	Alkermes' Q1 Earnings and Revenues Fall Short of Estimates (Zacks)
07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
May-01-25 10:40AM	Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
09:48AM	Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
07:57AM	UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales (Zacks)
Apr-30-25 12:17PM	Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y (Zacks)
09:07AM	Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
Apr-25-25 09:25AM	Beam Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +7.29%
Apr-10-25 09:49AM	Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? (Zacks) -10.63%
Apr-07-25 10:06AM	Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease (Benzinga)
Apr-05-25 07:00AM	Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress (GlobeNewswire)
Apr-01-25 12:42PM	Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? (Insider Monkey) -9.70%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-31-25 11:05AM	Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street (The Wall Street Journal) -12.07%
09:03AM	The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics (Zacks)
Mar-30-25 11:35AM	Street Calls of the Week (Investing.com)
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
09:26AM	BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance (Zacks)
Mar-27-25 04:01PM	Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration (GlobeNewswire)
11:30AM	Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-21-25 01:13PM	Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy (SeekingAlpha)
Mar-19-25 10:27AM	CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Mar-16-25 10:58AM	Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? (Insider Monkey)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-10-25 09:24AM	Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? (Insider Monkey) -9.80%
08:25AM	Beam base editing therapy gets proof of concept in rare lung disease (BioPharma Dive)
06:01AM	Beam Therapeutics Announces Pricing of Underwritten Offering (GlobeNewswire)
06:00AM	Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation (GlobeNewswire)
Mar-04-25 09:00PM	Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14% (Benzinga) +5.34%
Feb-25-25 08:15AM	Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts (GlobeNewswire)
Feb-24-25 10:07AM	Cathie Wood buys $11 million of under-the-radar AI stock (TheStreet)
07:00AM	Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences (GlobeNewswire)
Feb-23-25 03:05PM	Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-13-25 09:55AM	Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High? (Zacks)
Feb-10-25 09:40AM	Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year? (Zacks)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '25	Sale	24.53	467	11,456	44,045	Oct 03 04:15 PM
Bellon Christine	Chief Legal Officer	Oct 01 '25	Sale	24.53	373	9,150	116,921	Oct 03 04:10 PM
Evans John M.	CEO	Oct 01 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Sale	24.63	25,000	615,668	986,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 01 '25	Sale	24.51	25,000	612,655	986,667	Oct 03 04:05 PM
JOHN M EVANS	Officer	Oct 02 '25	Proposed Sale	24.63	25,000	615,668		Oct 02 04:23 PM
JOHN M EVANS	Officer	Oct 01 '25	Proposed Sale	24.51	25,000	612,655		Oct 01 04:12 PM
FMR LLC	See Remark 1	Jul 30 '25	Sale	20.50	48,374	991,667	2,073,665	Aug 01 09:36 AM
Simon Amy	Chief Medical Officer	Jul 03 '25	Sale	20.12	876	17,625	64,864	Jul 03 05:30 PM
Simon Amy	Chief Medical Officer	Jul 01 '25	Sale	16.94	374	6,336	65,740	Jul 03 05:30 PM
Bellon Christine	Chief Legal Officer	Apr 01 '25	Sale	18.35	5,674	104,122	117,294	Apr 03 09:53 PM
Evans John M.	CEO	Apr 01 '25	Sale	18.35	30,663	562,684	986,249	Apr 03 09:52 PM
Ciaramella Giuseppe	President	Apr 01 '25	Sale	18.35	7,434	136,418	190,216	Apr 03 09:51 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Apr 01 '25	Sale	18.35	3,015	55,330	44,512	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 02 '25	Sale	17.73	20,997	372,294	65,742	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 01 '25	Sale	18.35	9,566	175,542	86,739	Apr 03 09:50 PM
AMY SIMON	Officer	Apr 02 '25	Proposed Sale	17.73	20,997	372,294		Apr 02 04:08 PM
AMY SIMON	Officer	Apr 01 '25	Proposed Sale	22.21	30,562	678,782		Mar 31 06:44 PM
JOHN M. EVANS	Officer	Apr 01 '25	Proposed Sale	22.21	64,842	1,440,141		Mar 31 06:43 PM
CHRISTINE BELLON	Officer	Apr 01 '25	Proposed Sale	22.21	18,125	402,556		Mar 31 06:43 PM
GIUSEPPE CIARAMELLA	Officer	Apr 01 '25	Proposed Sale	22.21	23,750	527,488		Mar 31 06:43 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Feb 18 '25	Sale	35.00	6,287	220,045	37,527	Feb 20 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Option Exercise	7.22	10,000	72,200	112,968	Feb 19 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Sale	34.00	10,000	340,000	102,968	Feb 19 04:10 PM
CHRISTINE BELLON	Officer	Feb 14 '25	Proposed Sale	34.00	10,000	340,000		Feb 14 04:06 PM
Evans John M.	CEO	Jan 30 '25	Sale	26.75	30,000	802,484	908,659	Feb 03 04:05 PM
JOHN M EVANS	Officer	Jan 30 '25	Proposed Sale	26.75	30,000	802,482		Jan 30 04:12 PM
Bellon Christine	Chief Legal Officer	Jan 02 '25	Sale	24.68	1,241	30,628	102,968	Jan 06 05:49 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 02 '25	Sale	24.68	1,117	27,568	43,814	Jan 06 05:48 PM
BETHANY J. CAVANAGH	Officer	Dec 31 '24	Proposed Sale	25.27	9,500	240,065		Dec 30 07:29 PM
CHRISTINE BELLON	Officer	Dec 31 '24	Proposed Sale	25.27	4,167	105,300		Dec 30 07:26 PM
Ciaramella Giuseppe	President	Dec 17 '24	Option Exercise	0.67	53,500	35,845	162,650	Dec 19 04:10 PM
Ciaramella Giuseppe	President	Nov 06 '24	Sale	26.36	51,110	1,347,050	109,150	Nov 08 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BEAM

Beam Therapeutics Inc

Upgrade your FINVIZ experience